Clinical trials recruiting for MET Amplification
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| APL-101 Oral Capsules | 1 |
| Carboplatin | 1 |
| LMV-12(HE003) | 1 |
| Nab-paclitaxel | 1 |
| Pemetrexed | 1 |
| Toripalimab | 1 |
| • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 1 |
| Florida | 1 |
| Massachusetts | 1 |
| North Carolina | 1 |
| Pennsylvania | 1 |
| Wisconsin | 1 |
Top cities
Self-screener
Recruiting trials
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
- Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
- The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Related conditions
Trials recruiting for MET Amplification often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for MET Amplification trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.